Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer

NCT07714447 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

91

Enrollment

OTHER

Sponsor class

Conditions

CRC (Colorectal Cancer)
BRAF

Interventions

DRUG: Arm1
DRUG: Arm 2
DRUG: Arm 3

Sponsor

Sun Yat-sen University